Associated Papers
A single evolutionarily divergent mutation determines the different FAD-binding affinities of human and rat NQO1 due to site-specific phosphorylation.
Pacheco-Garcia JL et al.
Febs Letters, 2022
NAD(P)H quinone oxidoreductase (NQO1): an enzyme which needs just enough mobility, in just the right places.
Pey AL et al.
Bioscience Reports, 2019
Evolutionary Divergent Suppressor Mutations in Conformational Diseases.
Mesa-Torres N et al.
Genes, 2018
Natural (and Unnatural) Small Molecules as Pharmacological Chaperones and Inhibitors in Cancer.
Betancor-Fernández I et al.
Handbook of Experimental Pharmacology, 2018
Thermodynamics of cooperative binding of FAD to human NQO1: Implications to understanding cofactor-dependent function and stability of the flavoproteome.
Clavería-Gimeno R et al.
Archives of Biochemistry and Biophysics, 2017
Enhanced vulnerability of human proteins towards disease-associated inactivation through divergent evolution.
Medina-Carmona E et al.
Human Molecular Genetics, 2017
A mechanism for cancer-associated inactivation of NQO1 due to P187S and its reactivation by the consensus mutation H80R.
Muñoz IG et al.
Febs Letters, 2017
NQO1: A target for the treatment of cancer and neurological diseases, and a model to understand loss of function disease mechanisms.
Beaver SK et al.
Biochimica Et Biophysica Acta. Proteins and Proteomics, 0
Select a paper to view details